MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

Search

Xenon Pharmaceuticals Inc

Closed

SectorHealthcare

32.59 1.24

Overview

Share price change

24h

Current

Min

32.11

Max

33.1

Key metrics

By Trading Economics

Income

638K

-65M

Sales

7.5M

7.5M

Profit margin

-867.293

Employees

316

EBITDA

4.1M

-73M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+71.78% upside

Dividends

By Dow Jones

Next Earnings

7 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-303M

2.4B

Previous open

31.35

Previous close

32.59

News Sentiment

By Acuity

30%

70%

64 / 376 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Xenon Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

14 Jul 2025, 22:07 UTC

Major Market Movers

Trade Desk Rises on S&P 500 Inclusion

14 Jul 2025, 17:06 UTC

Major Market Movers

Crypto Assets Rally Ahead of Possible U.S. Legislation

14 Jul 2025, 16:47 UTC

Acquisitions, Mergers, Takeovers

NatWest to Sell Stake in Permanent TSB

14 Jul 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

14 Jul 2025, 23:38 UTC

Market Talk

Gold Edges Higher Ahead of U.S. CPI Data -- Market Talk

14 Jul 2025, 23:37 UTC

Market Talk

ANZ's Institutional Earnings Likely to Weigh on Outlook -- Market Talk

14 Jul 2025, 23:29 UTC

Market Talk

South32 Bull Eyes Possible Last-Minute Power Deal for Mozal -- Market Talk

14 Jul 2025, 23:29 UTC

Market Talk

Global Energy Roundup: Market Talk

14 Jul 2025, 23:02 UTC

Earnings

China Vanke: Additional Provision for Asset Impairment Also Among Factors Weighing on Results >000002.SZ

14 Jul 2025, 23:02 UTC

Earnings

China Vanke: Weakness in Overall China Real-Estate Sector Weighed on Results >000002.SZ

14 Jul 2025, 23:02 UTC

Earnings

China Vanke 1H Loss Was CNY9.85B >000002.SZ

14 Jul 2025, 23:01 UTC

Earnings

China Vanke Sees 1H Loss CNY10.0B-Loss CNY12.0B >000002.SZ

14 Jul 2025, 23:01 UTC

Earnings

China Vanke Expects 1H Loss to Widen >000002.SZ

14 Jul 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

14 Jul 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

14 Jul 2025, 20:07 UTC

Market Talk

Cloud Computing Giants Will Be the Winner from Software's Loss -- Market Talk

14 Jul 2025, 20:05 UTC

Market Talk

Adobe and Salesforce May Struggle to Keep Up With AI Agents -- Market Talk

14 Jul 2025, 19:11 UTC

Market Talk

Oil Retreats Despite Trump Threats of Russia Sanctions -- Market Talk

14 Jul 2025, 19:09 UTC

Market Talk

Gold Breaks a 3-Day Win Streak -- Market Talk

14 Jul 2025, 18:59 UTC

Market Talk

Hotter Weather Outlook, LNG Flows Boost U.S. Natural Gas -- Market Talk

14 Jul 2025, 18:30 UTC

Acquisitions, Mergers, Takeovers

Synopsys Buy of Ansys Gets China OK. The $35 Billion Deal Is Set to Close. -- Barrons.com

14 Jul 2025, 18:25 UTC

Market Talk

Dollar Gains, Treasury Yields Lose Steam as Trump Threatens Russia -- Market Talk

14 Jul 2025, 18:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 Jul 2025, 16:59 UTC

Market Talk

Goldman Sachs Lifts 2H25 Crude Price Views -- Market Talk

14 Jul 2025, 16:53 UTC

Hot Stocks

Stocks to Watch Monday: Kenvue, Tesla, Synopsys, Robinhood -- WSJ

14 Jul 2025, 16:27 UTC

Market Talk

Oil Falls as Investors Monitor U.S.-EU Trade, Trump's Russia Sanction Threats -- Market Talk

14 Jul 2025, 16:20 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

14 Jul 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

14 Jul 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14 Jul 2025, 16:12 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

Peer Comparison

Price change

Xenon Pharmaceuticals Inc Forecast

Price Target

By TipRanks

71.78% upside

12 Months Forecast

Average 55.33 USD  71.78%

High 65 USD

Low 47 USD

Based on 15 Wall Street analysts offering 12 month price targets forXenon Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

15 ratings

15

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

34.81 / 38.24Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Neutral Evidence

Sentiment

By Acuity

64 / 376 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.